Bei Akademie registrieren
BBIO, US10806X1028

BridgeBio Pharma stock nears key BBP-418 FDA decision

Published on 11/05/2026 at 01:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BridgeBio Pharma stock is heading toward a November 27 FDA decision for BBP-418. Third-quarter revenue rose to USD 353.2 million.

BridgeBio's pipeline enters key FDA phase

  • The FDA set November 27, 2026, as the PDUFA date for BBP-418, which has Priority Review.
  • BridgeBio reported third-quarter revenue of USD 353.2 million, led by USD 253.2 million in U.S. Attruby net product revenue.
  • Two further Priority Review decisions are scheduled for oral infigratinib in February 2027 and encaleret in May 2027.
BBIO, US10806X1028, Illustration mit AI erstellt.
BBIO, US10806X1028, Illustration mit AI erstellt.

BridgeBio Pharma is approaching a key regulatory milestone after the U.S. Food and Drug Administration set November 27, 2026, as the PDUFA target action date for BBP-418. The company reported the date and its third-quarter results on October 29, 2026, in a BridgeBio Pharma investor release.

BBP-418 reaches FDA decision stage

BBP-418 is under Priority Review for limb-girdle muscular dystrophy type 2I/R9. BridgeBio said no advisory committee meeting is currently planned and that launch preparation is well advanced. The company intends to submit a European marketing application in the first half of 2028, based on the final Phase 3 FORTIFY analysis.

BridgeBio Pharma stock traded at 69.39 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of BridgeBio Pharma stock.

Revenue growth supports launch plans

BridgeBio reported third-quarter revenue of USD 353.2 million, compared with USD 120.7 million a year earlier. U.S. Attruby net product revenue contributed USD 253.2 million, while license and services revenue included a USD 75.0 million Bayer sales milestone. The company recorded an operating loss of USD 11.6 million and held USD 1.5 billion in cash, cash equivalents and marketable securities at September 30, 2026.

Two additional Priority Review decisions are scheduled within the following seven months. Oral infigratinib for achondroplasia has a February 4, 2027, PDUFA date, while encaleret for autosomal dominant hypocalcemia type 1 has a May 8, 2027, target action date. BridgeBio also said the first participant had been dosed in RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism, with topline data expected in early 2028.

BridgeBio's business and market position

BridgeBio Pharma develops and commercializes medicines for genetic conditions through a decentralized model that combines autonomous disease-focused teams with centralized clinical, regulatory and commercial capabilities. Its commercial portfolio includes Attruby for transthyretin amyloid cardiomyopathy, while its late-stage pipeline targets rare diseases including LGMD2I/R9, achondroplasia and ADH1. The company is based in Palo Alto, California, and is expanding from a commercial-stage platform toward several potential product launches.

The wider U.S. equity market remains relevant for biotechnology investors through the S&P 500.

More company developments and pipeline updates are available in more news and analyses on BridgeBio Pharma stock.

BridgeBio Pharma stock facts

  • Company: BridgeBio Pharma, Inc.
  • ISIN: US10806X1028
  • Ticker: BBIO
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 69.39 euros at 11:00 p.m. CET on November 4, 2026
  • Regulatory milestone: BBP-418 PDUFA date on November 27, 2026
Disclaimer...
en | US10806X1028 | BBIO | boerse | 70460201 |